Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
NCT03593499 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-05-31
Summary
This is an expanded access program for eligible participants and is designed to provide access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients who previously participated in the 408-C-1401 (REVEAL) study. To be considered for expanded access, a Principal Investigator from the REVEAL trial should submit a request to Reata Pharmaceuticals on behalf of the individual patient.
Conditions
Interventions
- DRUG
-
omaveloxolone
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
NCT00521053 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
NCT02147951 ·Status: NO_LONGER_AVAILABLE
-
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
NCT00109005 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142218 ·Status: NO_LONGER_AVAILABLE
-
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
NCT07040436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
NCT05928962 ·Status: UNKNOWN ·Phase: PHASE1
-
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
NCT02297529 ·Status: NO_LONGER_AVAILABLE
-
RAD001 Plus Bevacizumab in Metastatic Melanoma
NCT00591734 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
NCT03190824 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 ·Status: RECRUITING
-
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
NCT05903937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Intralesional PV-10 Chemoablation of Metastatic Melanoma
NCT00219843 ·Status: COMPLETED ·Phase: PHASE1
-
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
NCT03817125 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
NCT01864759 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
NCT02680184 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
NCT00091689 ·Status: COMPLETED ·Phase: PHASE1